AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Trial: NCT01210456
Drug: Physiological Saline, N-Acetylcysteine and Sodium Bicarbonate
FDA approved: no
EMA approved: no
PMDA approved: no
Description: All patients receive N-Acetylcysteine(NAC) and sodium chloride. NAC is given orally at a dose of 700mg twice daily, on the day before and on the day of administration of the contrast media, for a total of two days.~154mEq/L of sodium chloride is given intravenously. The initial intravenous bolus is 3ml/kg per hour for 1 hour immediately before contrast injection. And then, patients receive the same fluid at 1ml/kg per hour during the contrast exposure and for 6 hours after the procedure.~In addition, intervention arms receive sodium bicarbonate.1000mEq/L of sodium bicarbonate is given intravenously twice at a dose of 40ml immediately before the contrast exposure and immediately after the procedure.
Trial: NCT00821834
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Form: tablets~Route: oral
Trial: NCT02706236
Drug: placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo will consist of lactose, spread throughout the day with meals and snacks, taken daily PO for 4 weeks
Trial: NCT03808662
Drug: Standard of care
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Standard of care per physician discretion
Trial: NCT00158574
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo
Trial: NCT02202980
Drug: LDV/SOF
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 90/400 mg FDC tablet administered orally once daily
Trial: NCT02202980
Drug: SOF/VEL
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 400/100 mg FDC tablet administered orally once daily
Trial: NCT02503657
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Excipients of MN-001/tipelukast
Trial: NCT01995201
Drug: DMARD
RxNorm normalized name: Disease-modifying antirheumatic drug (DMARD)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: non-biological disease-modifying antirheumatic drugs at stable dose
Trial: NCT01995201
Drug: methotrexate
RxNorm normalized name: Methotrexate
DrugBank: Methotrexate (DB00563)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: stable dose
Trial: NCT03697746
Drug: Dexketoprofen Trometamol
RxNorm normalized name: Dexketoprofen trometamol
FDA approved: no
EMA approved: no
PMDA approved: no
Description: dexketoprofen trometamol 50 mg bulb
Trial: NCT03697746
Drug: Ibuprofen
RxNorm normalized name: Ibuprofen
DrugBank: Ibuprofen (DB01050)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: ıbuprofen 400 mg vial
Trial: NCT00237848
Drug: D-serine
RxNorm normalized name: D-Serine
DrugBank: D-Serine (DB03929)
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT00951301
Drug: placebo juice
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 6 ounces of specially prepared juice not containing mangosteen taken twice daily, AM and PM, for 6 months duration of the study participation.
Trial: NCT03420300
Drug: EBR/GZR
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Elbasvir/grazoprevir (EBR/GZR 50mg/100mg fixed dose combination \[FDC\]): 1 table per os per day for 12 weeks
Trial: NCT00515203
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Starting dose of 1.0 ug/kg. Dose adjustments are made throughout the study based on individual platelet counts.
Trial: NCT00799656
Drug: placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: oral administration once daily for 28 days
Trial: NCT00865904
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo matched to VX-809 capsules.
Trial: NCT01706536
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: EP-101 Placebo AM + EP-101 Placebo PM
Trial: NCT01706536
Drug: EP-101 12.5 mcg
FDA approved: no
EMA approved: no
PMDA approved: no
Description: EP-101 12.5 mcg AM + EP-101 12.5 mcg PM
Trial: NCT01706536
Drug: EP-101 25 mcg
RxNorm normalized name: acetaminophen
DrugBank: Acetaminophen (DB00316)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: EP-101 25 mcg AM + EP-101 25 mcg PM
Trial: NCT01706536
Drug: EP-101 50 mcg
RxNorm normalized name: acetaminophen
DrugBank: Acetaminophen (DB00316)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: EP-101 50 mcg AM + EP-101 50 mcg PM
Trial: NCT02024568
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: See arm description
Trial: NCT01706536
Drug: EP-101 100 mcg
RxNorm normalized name: acetaminophen
DrugBank: Acetaminophen (DB00316)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: EP-101 100 mcg AM + EP-101 100 mcg PM
Trial: NCT02126306
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: normal saline
Trial: NCT03262012
Drug: BFF MDI (PT009)
RxNorm normalized name: ethanol
DrugBank: Ethanol (DB00898)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Budesonide and Formoterol Fumarate Inhalation Aerosol, BFF MDI, PT009
Trial: NCT03262012
Drug: Symbicort® Turbohaler® Inhalation Powder
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Budesonide and Formoterol Fumarate Inhalation Powder, Symbicort® Turbohaler® Inhalation Powder, Symbicort Turbohaler
Trial: NCT03187002
Drug: Moderate IV Sedation
RxNorm normalized name: Tavist Non-Sedating
FDA approved: no
EMA approved: no
PMDA approved: no
Description: IV sedation with fentanyl and versed
Trial: NCT04149964
Drug: Acetaminophen 325 mg Oral Tablet
RxNorm normalized name: ACETAMINOPHEN 325 mg ORAL TABLET
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Standard of Care Acetaminophen 325 mg every 6 hours as needed for pain
Trial: NCT04149964
Drug: Acetaminophen 650 mg Oral Tablet
RxNorm normalized name: acetaminophen 650 mg oral tablet
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Acetaminophen 650 mg scheduled every 6 hours round the clock for pain
Trial: NCT03423225
Drug: ADVAGRAF®
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Administration method The total daily dose of tacrolimus will be converted to 1:1 (mg:mg) and the total daily dose of ADVAGRAF® will be administered only once daily in the morning, starting from Day 1 (at least one hour before breakfast or 2 to 3 hours after breakfast).~* Dose adjustment after conversion On Day 1, the total dose will be converted to 1:1. It is recommended to check the blood concentration of tacrolimus at each visit and adjust the dose to achieve the blood concentration maintaining at 5\~8ng/ml for 0 to 3 months and then at 5ng/ml or below for 3 to 6 months of study treatment.~* Duration of treatment The investigational product will be administered for 24 weeks.
Trial: NCT00741663
Drug: Spironolactone and furosemide
RxNorm normalized name: furosemide / spironolactone
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Patients in arm A will receive potassium canrenoate at the initial dose of 200 mg/day, then increased up to 400 mg/day. Non responders will be treated with 400 mg/day of potassium canrenoate and furosemide at an initial dose of 50 mg/day, then increased up to 150 mg/day.
Trial: NCT00741663
Drug: Spironolactone and furosemide
RxNorm normalized name: furosemide / spironolactone
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Patients in arm B will receive at first 200 mg/day of potassium canrenoate and 50 mg/day of furosemide, then increased up to 400 mg/day and 150 mg/day, respectively.
Trial: NCT01697696
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo to match QAB149
Trial: NCT03066453
Drug: Tobi Inhalant Product
RxNorm normalized name: Tobi Inhalant Product
FDA approved: no
EMA approved: no
PMDA approved: no
Description: inhaled tobramycin 300 mg twice per day
Trial: NCT04125706
Drug: Minocycline Topical
RxNorm normalized name: minocycline topical
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Minocycline will be delivered locally in the periodontal pocket
Trial: NCT00463606
Drug: ABT-335 and rosuvastatin calcium
RxNorm normalized name: ABT-925
FDA approved: no
EMA approved: no
PMDA approved: no
Description: ABT-335 135 mg in combination with rosuvastatin calcium 5 mg administered orally, once daily for 12 weeks
Trial: NCT00463606
Drug: ABT-335
RxNorm normalized name: ABT-925
FDA approved: no
EMA approved: no
PMDA approved: no
Description: ABT-335 135 mg monotherapy administered orally, once daily for 12 weeks
Trial: NCT00463606
Drug: rosuvastatin calcium
RxNorm normalized name: Rosuvastatin Calcium
DrugBank: Rosuvastatin (DB01098)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Rosuvastatin calcium 5 mg monotherapy administered orally, once daily for 12 weeks
Trial: NCT06266962
Drug: Epinephrine
RxNorm normalized name: Epinephrine
DrugBank: Epinephrine (DB00668)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Patients underwent the instillation of epinephrine into the anterior chamber at the beginning of the cataract surgery.
Trial: NCT01223365
Drug: Hydrocodone ER
RxNorm normalized name: hydrocodone Extended Release Oral Tablet
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Hydrocodone bitartrate extended-release tablets were administered at doses of 15, 30, 45, 60, and 90 mg orally every 12 hours. During the open-label titration period, doses were adjusted until a stable pain control was achieved. In general, the dose of hydrocodone extended release tablets could be adjusted for efficacy or tolerability, as necessary, at any time during the open-label treatment period; however, participants were required to visit the study center before increasing the dose of study drug.
Trial: NCT03482440
Drug: Salsalate Oral Tablet
RxNorm normalized name: salsalate Oral Tablet
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 1500mg twice daily for 5 days prior to experimental testing
Trial: NCT03482440
Drug: Placebo Oral Tablet
RxNorm normalized name: placebo ORAL TABLET
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo oral table twice daily for 5 days prior to experimental testing
Trial: NCT00431691
Drug: 100% O2
FDA approved: no
EMA approved: no
PMDA approved: no
Description: breathing for 30 minutes, 2 breathing periods on both study days
Trial: NCT00003422
Drug: fluorouracil
RxNorm normalized name: Fluorouracil
DrugBank: Fluorouracil (DB00544)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Trial: NCT00003422
Drug: leucovorin calcium
RxNorm normalized name: Leucovorin Calcium
DrugBank: Leucovorin (DB00650)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Trial: NCT00884169
Drug: M518101
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Proper quantity twice a day
Trial: NCT00884169
Drug: placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Proper quantity twice a day
Trial: NCT03822078
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Administered by subcutaneous injection
Trial: NCT01110447
Drug: VSL#3
RxNorm normalized name: VSL#3
FDA approved: no
EMA approved: no
PMDA approved: no
Description: VSL#3® is made up of 4 strains of Lactobacilli (L. paracasei, L. plantarum, L. acidophilus and L. delbrueckii subsp. bulgaricus), 3 strains of Bifidobacteria (B. longum, B. infantis, B. breve) and 1 strain of Streptococcus thermophilus. Dose would be 1 sachet per day (Each sachet containing 900 Billion CFU). The duration of treatment would be for 24 weeks
Trial: NCT00322257
Drug: inhaled human insulin
RxNorm normalized name: insulin, regular, human Inhalation Powder
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Treat-to-target dose titration scheme, inhalation.
Trial: NCT03758001
Drug: IBI101
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 0.01 mg/kg; 0.1 mg/kg; 0.3 mg/kg; 1 mg/kg; 3 mg/kg; 6 mg/kg; 10 mg/kg; 15 mg/kg iv infusion day 1 of every 21 days
Trial: NCT03758001
Drug: IBI101
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 1 mg/kg; 3 mg/kg; 6 mg/kg; 10 mg/kg iv infusion day 1 of every 21 days
Trial: NCT01466335
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: matching placebo tablet
Trial: NCT02857270
Drug: LY3214996
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Administered orally
Trial: NCT00884988
Drug: Lymphomyosot
RxNorm normalized name: Lymphomyosot Solution for Injection
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 20 drops X3/day, until discharge
Trial: NCT00884988
Drug: Placebo remedy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 20 drops X3/day, until discharge
Trial: NCT02541526
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Similar capsule containing placebo will be started on day six of treatment for a period of 3 days followed by two capsules of placebo daily for a period of four months
Trial: NCT04526210
Drug: ALXN1840
FDA approved: no
EMA approved: no
PMDA approved: no
Description: ALXN1840 will be administered orally as a single dose as 4 x 15 mg enteric-coated tablets with 240 milliliters of water (fasting), for a total dose of 60 mg.
Trial: NCT02370745
Drug: GIP
RxNorm normalized name: GIP
FDA approved: no
EMA approved: no
PMDA approved: no
Description: This will be co infused with GLP-1 and intravenous amino acids
Trial: NCT00555971
Drug: placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Subjects randomized to Placebo prior to aspirin desensitization
Trial: NCT00458848
Drug: mercaptopurine
RxNorm normalized name: Mercaptopurine
DrugBank: Mercaptopurine (DB01033)
FDA approved: yes
EMA approved: no
PMDA approved: no
Trial: NCT00458848
Drug: methotrexate
RxNorm normalized name: Methotrexate
DrugBank: Methotrexate (DB00563)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Trial: NCT04629404
Drug: LY03003
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Firstly, intramuscularly inject 14 mg of the study drug once, continue intramuscularly inject 28 mg of the study drug once after being observed for 1 week to confirm safety, continue intramuscularly inject 42 mg of the study drug once after being observed for 1 week to confirm safety, and prepare to enter the maintenance period of 56 mg dose after being observed for 1 week to confirm safety. During the dose maintenance period, 56 mg of the test drug was intramuscularly injected once a week for a total of 4 consecutive doses.
Trial: NCT04629404
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Firstly, intramuscularly inject 14 mg of the study drug once, continue intramuscularly inject 28 mg of the study drug once after being observed for 1 week to confirm safety, continue intramuscularly inject 42 mg of the study drug once after being observed for 1 week to confirm safety, and prepare to enter the maintenance period of 56 mg dose after being observed for 1 week to confirm safety. During the dose maintenance period, 56 mg of the test drug was intramuscularly injected once a week for a total of 4 consecutive doses.
Trial: NCT01179880
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Matching placebo for each step
Trial: NCT01703832
Drug: Neurexan®
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 0.6 mg / tablet, 6 tablets, 1 tablet every 30 minutes from -180 minutes to -30 minutes
Trial: NCT03561142
Drug: Chemotherapy
RxNorm normalized name: Chemotherapy Glove SML
FDA approved: no
EMA approved: no
PMDA approved: no
Description: chemoradiotherapy is started according to the following schedule: 5-FU: 250 mg/sqm per day, iv, on day 1-14, day 22-35; Oxaliplatin: 50 mg/sqm, day 1, 8, 22, and 29. After a break of two and a half weeks, patients receive three chemotherapy cycles, starting on day 57, 71 and 85, consisting of: Folinic acid: 400 mg/sqm, 2h-iv; Oxaliplatin: 100 mg/sqm, 2h-iv; 5-FU: 2400 mg/sqm, 46h-iv
Trial: NCT00893256
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo: once daily
Trial: NCT03365037
Drug: Electret electrostatic physiotherapyFilm
RxNorm normalized name: ELECARE JR
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Patients with acute soft tissue injury treated with electret electrostatic physiotherapyFilm
Trial: NCT04352361
Drug: TVB-2640
FDA approved: no
EMA approved: no
PMDA approved: no
Description: TVB-2640 tablets (25mg/50mg/75mg) one tablet at a time, once per day.
Trial: NCT04352361
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral, matching number of placebo Tablets with active arm.
Trial: NCT04227483
Drug: Prednisolone
RxNorm normalized name: Prednisolone
DrugBank: Prednisolone acetate (DB15566)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Prednisolone for 4 months
Trial: NCT04550260
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Durvalumab matching placebo for intravenous infusion
Trial: NCT02679001
Drug: TNF inhibitor/TCZ
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Participants with RA receiving TNF-inhibitor or TCZ according to standard of care and in line with the current SPC/local labeling will be observed.
Trial: NCT04550260
Drug: cisplatin + fluorouracil
RxNorm normalized name: Cisplatin
DrugBank: Cisplatin (DB00515)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: cisplatin + fluorouracil, as per Standard of Care
Trial: NCT04550260
Drug: cisplatin + capecitabine
RxNorm normalized name: Capecitabine
DrugBank: Capecitabine (DB01101)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: cisplatin + capecitabine, as per Standard of Care
Trial: NCT02800252
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: One-stage full-mouth periodontal ultrasonic debridement plus placebo intervention
Trial: NCT01709760
Drug: Methotrexate
RxNorm normalized name: Methotrexate
DrugBank: Methotrexate (DB00563)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Methotrexate 15-25 mg/week
Trial: NCT01709760
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo, sc twice weekly
Trial: NCT02800252
Drug: 3g omega-3 plus 100mg aspirin daily for 60 days
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Full-mouth periodontal debridement, 3g omega-3 plus 100mg aspirin daily for 60 days after periodontal therapy
Trial: NCT00647881
Drug: Paxil CR™ Tablets 25 mg
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 25mg, single dose fed
Trial: NCT02800252
Drug: omega-3 plus aspirin before periodontal therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Full-mouth periodontal debridement, 3g omega-3 plus 100mg aspirin daily for 60 days before periodontal therapy
Trial: NCT00150007
Drug: Enteric-coated Mycophenolate sodium (EC-MPS)
RxNorm normalized name: mycophenolic acid
DrugBank: Mycophenolic acid (DB01024)
FDA approved: yes
EMA approved: no
PMDA approved: no
Trial: NCT04408755
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: oral capsules
Trial: NCT04088760
Drug: TCRαβ+/CD19+ depleted allogeneic hematopoietic stem cell transplant (HSCT)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: The majority of TCRαβ+ T cells and CD19+ B cells will be removed from the allogeneic graft utilizing the CliniMACS® immunomagnetic selection device (Miltenyi Biotec). The depletion process involves two phases; cell labeling (phase 1) and the automated immunomagnetic depletion process (phase 2). The CD34+ dose may be adjusted by the need to not exceed the TCRαβ+CD3+ dose threshold.
Trial: NCT04258865
Drug: CKD-828, D097, D337
FDA approved: no
EMA approved: no
PMDA approved: no
Description: QD, PO
Trial: NCT00193037
Drug: Liposomal Doxorubicin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Liposomal Doxorubicin
Trial: NCT03748082
Drug: Nitric Oxide
RxNorm normalized name: Nitric Oxide
DrugBank: Nitric Oxide (DB00435)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Inhaled nitric oxide (iNO) will be administered via the CPB machine and after CPB via the inspiratory limb of the anesthetic or ventilator circuit, and thereafter via the mechanical ventilator in the ICU. Test gas administration will commence at the onset of CPB and last for 24 hours. At the end of 24 hours, iNO will be weaned and discontinued.
Trial: NCT00908778
Drug: Vitreosolve
FDA approved: no
EMA approved: no
PMDA approved: no
Description: intravitreal injection
Trial: NCT04353791
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo
Trial: NCT01391793
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Twice daily for 3 days
Trial: NCT02962076
Drug: [C-11] Meta-hydroxyephedrine radioactive tracer (MHED)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: this tracer detects the distribution of sympathetic nerve fibers in the left ventricle
Trial: NCT00390065
Drug: Nitric Oxide
RxNorm normalized name: Nitric Oxide
DrugBank: Nitric Oxide (DB00435)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Early low dose (5ppm) NO inhalation Placebo
Trial: NCT01666730
Drug: leucovorin calcium
RxNorm normalized name: Leucovorin Calcium
DrugBank: Leucovorin (DB00650)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Given IV
Trial: NCT01666730
Drug: fluorouracil
RxNorm normalized name: Fluorouracil
DrugBank: Fluorouracil (DB00544)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Given IV
Trial: NCT02296320
Drug: MEDI4893
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Participants will receive a single IV dose of MEDI4893 2000 or 5000 mg on Day 1 of the study.
Trial: NCT03006445
Drug: FYU-981
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT01184391
Drug: DEPAKOTE® Tablets, 500 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 1 x 500 mg tablet, under fasting conditions
Trial: NCT01577121
Drug: indomethacin
RxNorm normalized name: Indomethacin
DrugBank: Indomethacin (DB00328)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: 50 mg / 6 hours during 5 days
Trial: NCT01735630
Drug: ELND005
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT01735630
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT01577121
Drug: placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 50 mg / 6 hours during 5 days
Trial: NCT00172055
Drug: Zoledronic acid
RxNorm normalized name: Zoledronic Acid
DrugBank: Zoledronic acid (DB00399)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Trial: NCT01522664
Drug: DEDN6526A
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Multiple ascending doses
Trial: NCT01104766
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Patients who meet eligibility criteria will be administered a once daily oral dose of placebo for six weeks. Upon completion of the study or early termination, patients will undergo a two week safety follow-up period.